Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo-controlled phase 1 study of DNL201 in healthy volunteer.A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of DNL201 in Healthy Subjects

Trial Profile

A randomized, double blind, placebo-controlled phase 1 study of DNL201 in healthy volunteer.A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of DNL201 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL-201 (Primary)
  • Indications Parkinson's disease
  • Focus First in man; Pharmacokinetics
  • Sponsors Denali Therapeutics Inc
  • Most Recent Events

    • 06 Aug 2020 Status changed from recruiting to completed, according to a Denali Therapeutics Inc media release.
    • 08 Nov 2018 According to a Denali Therapeutics Inc media release, data were presented at the Michael J. Fox Foundation Parkinson's Disease Therapeutic Conference. The results met all endpoints.
    • 01 Aug 2018 According to a Denali Therapeutics Inc media release, company has announced positive results of this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top